Physician profile
Astrid E Morrison
NPI 1356348171
$837.63
in general payments reported to CMS, 2019-2025
23 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $68.84 · 2021: $35.90 · 2022: $198 · 2023: $155 · 2024: $101 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $389.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $201.62 | 2019-2025 | Optune Gio |
| Novartis Pharmaceuticals Corporation | $114.11 | 2022-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $45.69 | 2022-2023 | Epkinly, Imbruvica |
| Incyte Corporation | $37.53 | 2023-2024 | Monjuvi, Jakafi |
| Fortovia Therapeutics, INC. | $36.72 | 2019 | |
| Siemens Medical Solutions USA, INC. | $36.26 | 2022-2025 | Eclipse Treatment Planning System For External Beam Radiation Therapy |
| Varian Medical Systems, INC. | $34.51 | 2019 | |
| Boston Scientific Corporation | $32.15 | 2019-2020 | |
| Emd Serono, INC. | $28.00 | 2022-2023 | Bavencio |
| Merck Sharp & Dohme LLC | $26.73 | 2024 | Keytruda |
| Astellas Pharma US INC | $26.68 | 2022-2023 | |
| Progenics Pharmaceuticals, INC. | $24.19 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $23.50 | 2024 | Libtayo |
| Coherus Oncology, INC. | $22.19 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.79 | 2023 | Ninlaro |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $20.66 | 2023 | Myrisk |
| Caris Mpi, INC. | $19.25 | 2025 | Mi Cancer Seek |
| Karyopharm Therapeutics INC. | $18.18 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.53 | 2022 | |
| Puma Biotechnology, INC. | $13.13 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $12.94 | 2021 | |
| Advanced Accelerator Applications | $12.76 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Astrid Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.